Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Castle Biosciences Earnings Call: Key Takeaways

Castle Biosciences delivered a strong Q3 2026 beat, raising full-year revenue guidance by $20 million driven by 47% volume growth in TissueCypher.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue up 24% to $102.9M; TissueCypher revenue primary driver.
Mgmt ConfidenceHigh confidence in core drivers; raised full-year midpoint guidance by $20M.
Demand VisibilityTissueCypher 15% penetrated; DecisionDX-Melanoma fifth quarter exceeding 10,000 reports.
Margin TrendsAdjusted gross margin steady at 77%; efficiencies offsetting higher lab costs.
Op. LeverageScaling lab headcount with volume but achieving incremental efficiency gains.
Pricing PowerASP improvements in core products; seeking crosswalk pricing for IDDX-AD.
Vol vs PriceVolume-led growth in TissueCypher (47%); mid-single digit growth in Melanoma.
Segment GrowthTissueCypher volume up 47%; DecisionDX-Melanoma volume up 5% year-to-date.
New ClientsAdding new ordering clinicians for TissueCypher; 100-person sales teams sufficient.
Capex & DebtEnded quarter with $278M cash; $19.7M net cash from operations.
RegulatoryCMS proposed gapfill for ADTX; SCC Medicare coverage not expected until 2028.
CommentaryFocusing on clinical evidence to drive adoption in under-penetrated Barrett's market.
New LaunchesIntegrating Esopredict acquisition to provide answers when TissueCypher samples fail.

Growth

Revenue grew 24% to $102.9M; TissueCypher volumes surged 47% to 15,574 reports.

Outlook

Raised 2026 revenue guidance to $385M-$395M; positive adjusted EBITDA expected for 2027.

Risks

Management pivoted on specific SCC Medicare coverage timelines, pushing recovery expectations into 2028.

Source

The company's earnings call, NASDAQ: CSTL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Castle Biosciences Inc: key numbers

Share price
$32.75Close, Nov 16
Market cap
$1.01B
Shares outstanding
30.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Castle Biosciences Inc

All →
4:06 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).

Value
$112K
Shares
3,195
Price
$35.07
Role
Chief Commercial Officer
Holding change
-8.9%
Trade date
Nov 11, 2026
4:13 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).

Value
$207K
Shares
6,116
Average price
$33.77
Role
Chief Commercial Officer
Holding change
-8.0%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:12 PM ET 10-Q
Financial Results ▶ Call

Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens

Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.

Key figure
Net loss $4.1M
4:11 PM ET 8-K
Financial Results

Castle Biosciences Financial Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.

Term
Q3 2026

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”

Derek Maetzold, president and chief executive officer of Castle Biosciences
4:08 PM ET Form 4
Insider Selling

Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $523K of Stock

Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $36.01 to $36.81 a share (average $36.10) in 6 transactions, worth $523K in total on Nov 2, 2026. Shares held after the trade: 1,396 (-18.9%).

Value
$523K
Shares
14,496
Average price
$36.10
Role
Pres. & Chief Exec. Officer
Holding change
-18.9%
Trade date
Nov 2, 2026
4:06 PM ET Form 4
Insider Selling

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $240K of Stock

Tobin W. Juvenal, Chief Commercial Officer, sold 6,578 shares of Castle Biosciences Inc at $35.58 to $36.62 a share (average $36.42) in 2 transactions, worth $240K in total on Oct 28, 2026. Shares held after the trade: 38,853 (-12.1%).

Value
$240K
Shares
6,578
Average price
$36.42
Role
Chief Commercial Officer
Holding change
-12.1%
Trade date
Oct 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.